J.Safra Asset Management Corp Ascendis Pharma A/S Transaction History
J.Safra Asset Management Corp
- $1.2 Billion
- Q4 2024
A detailed history of J.Safra Asset Management Corp transactions in Ascendis Pharma A/S stock. As of the latest transaction made, J.Safra Asset Management Corp holds 141 shares of ASND stock, worth $21,925. This represents 0.0% of its overall portfolio holdings.
Number of Shares
141
Previous 103
36.89%
Holding current value
$21,925
Previous $15,000
26.67%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ASND
# of Institutions
236Shares Held
59.5MCall Options Held
80.3KPut Options Held
216K-
Ra Capital Management, L.P. Boston, MA10.1MShares$1.57 Billion22.55% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.53MShares$860 Million3.52% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.1MShares$794 Million10.24% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.45MShares$692 Million0.98% of portfolio
-
Janus Henderson Group PLC London, X04.38MShares$681 Million0.32% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $8.68B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...